Supporters of Donald Trump are split on the question of whether he should run for president again in 2024. That’s according to the latest unscientific poll of 2,559 people at SharylAttkisson.com. Nearly 50% of those who responded said they are […]
POLL: Trump supporters split on whether he should run in 2024 Read More »
Congress has shepherded in the quiet return of one of the most controversial spending practices in Washington D.C.
After Hours: Earmarks — They’re ba-aaack! (PODCAST) Read More »
There’s been a mass exodus from America’s public schools systems. When schools opened back up again after lengthy Covid shutdowns, not all the children came back. Parents who’d never considered home schooling gave it a try and found they were
Mass Public School Exodus; Ukraine in US Politics; Drones in Israel Read More »
TV cameras in courtrooms have been the subject of debate for a century. Sunday on Full Measure, we’ll look at some of the most memorable televised court cases. We’ll also talk to Sen. Chuck Grassley about a bipartisan effort to
TV Cameras in Court; Ft. Detrick and Covid; Niagara Falls Read More »
March 23, 2022 Statement by Donald J. Trump, 45th President of the United States of America The “Blue Monster” at Doral has undergone millions of dollars of upgrades and renovations. It continues to be one of the great tournament courses
In today’s confirmation hearings for Supreme Court nominee Ketanji Jackson, she indicated that she considers child pornography a very serious and despicable crime. However, she indicated (my interpretation) that distributing or viewing thousands of images in a matter of minutes
(FORUM) Is child porn less serious when it’s easy to access? Read More »
Quiz yourself: Which photos can you match to a famous or infamous trial? Then watch @FullMeasureNews this Sunday for the answers and an engaging look at TV cameras in the courtroom and what comes next. Watch Full Measure Sunday March
An Alzheimer’s drug brought to market in one of the most controversial FDA approval processes ever– is the subject of my cover story this week on Full Measure. Aducanumab, now sold as Aduhelm, was introduced last June at a cost
